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Background: Noncancerous causes of death, such as cerebrovascular or cardiac disease, are not rare in patients
with gastric cancer who had undergone curative gastrectomy. Metabolic syndrome, characterized by visceral fat
accumulation, is a risk factor for cerebrovascular and cardiac diseases. However, there is limited information on the
effects of reconstruction procedures on changes in visceral fat after distal gastrectomy. The aim of this study was to
analyze the impact of the reconstruction procedure (Roux-en-Y reconstruction (RY) and Billroth I reconstruction (BI))
on changes in visceral fat, as determined using computed tomography.
Methods: The study subjects were 152 patients with gastric cancer who underwent distal gastrectomy with
lymphadenectomy between 2002 and 2007. The visceral fat area was measured for one cross-sectional computed
tomogram obtained at the level of the umbilicus.
Results: Adjuvant chemotherapy (yes vs. no, P = 0.0006), type of reconstruction (BI vs. RY, P = 0.0146), field of
lymph node dissection (<D2 vs. ≥D2, P = 0.0020), omentectomy (yes vs. no, P = 0.0003), and pathological stage
(1/2 vs. 3/4; P = 0.0023) correlated significantly with postoperative visceral fat loss. Multivariate logistic regression
analysis identified reconstruction (BI vs. RY; P = 0.0232) and adjuvant chemotherapy (yes vs. no, P = 0.0330) as the
significant determinants of visceral fat loss after surgery.
Conclusions: Visceral fat loss after RY was larger than that after BI. Further prospective studies are needed to
confirm the effects of reconstruction after distal gastrectomy on visceral fat.
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Noncancerous death is a common cause of death in pa-
tients with gastric cancer who had undergone curative
gastrectomy. This is probably because the 5-year survival
rate has improved to about 95%, especially in patients with
early gastric cancer treated by radical resection [1]. The
causes of noncancerous deaths include cerebrovascular,
cardiac, and respiratory diseases [2]. The metabolic syn-
drome, characterized by visceral fat accumulation, is a risk
factor for cerebrovascular and cardiac diseases [3-5]. The
Roux-en-Y gastric bypass is a popular procedure used to
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reproduction in any medium, provided the orsubjects. Although Roux-en-Y (RY) gastric bypass and
Roux-en-Y reconstruction after gastrectomy for gastric
cancer are not entirely similar, the selection of reconstruc-
tion method could control visceral fat after gastrectomy
for gastric cancer.
Several studies have reported poor prognosis of pa-
tients with excess post-gastrectomy body weight loss
[6,7]. Body weight loss is a serious problem, especially
for lean patients. Such weight loss is caused by impaired
food intake and malabsorption [8-10] Body weight loss
after gastrectomy is thought to be mainly due to loss of
body fat (which includes subcutaneous and visceral fat)
[11-13]. In this regard, visceral fat change is worthy of
remark. However, to our knowledge, there is no infor-
mation on changes in visceral fat and subcutaneous fatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dures, such as distal gastrectomy with Billroth I (DGBI)
reconstruction or distal gastrectomy with Roux-en-Y
(DGRY) reconstruction.
In this retrospective study, we first quantified the vis-
ceral fat area (VFA) and then determined the impact of
different surgical procedures (DGBI and DGRY) on the
visceral fat of patients who underwent distal gastrectomy
with lymphadenectomy. Clinically, this study serves to
provide a basis for appropriate selection of reconstruc-
tion method following distal gastrectomy, to provide
adequate control of visceral fat volume postoperatively
in the long-term.
Methods
Patients and surgical procedures
Between January 2002 and April 2007, a total of 152 pa-
tients with gastric cancer underwent distal gastrectomy
with lymphadenectomy at the Osaka Medical Center for
Cancer and Cardiovascular Diseases, Osaka, Japan. They
included 106 men and 46 women with a mean age of
62.8 ± 9.8 years (±SD, range: 37 to 85 years; median: 63
years). All patients underwent preoperative assessment,
including gastric endoscopy, computed tomography
(CT) and laboratory tests. In this study, we compared
the CT images taken at least 6 months after surgery with
those before surgery.
Roux-en-Y reconstruction was performed when the
remnant stomach after resection was too small to allowFigure 1 CT images obtained at the navel level demonstrating the m
(arrowed) outlines the intraperitoneal area. (b) The line (arrowed), drawn w
layer, in which attenuation is measured. (c) A histogram of the CT numbers
(d) Measurement of visceral fat tissue (solid arrow). The total fat area is rep
abdominal wall. The visceral fat area was subtracted, and the remainder waperformance of BI or when the main tumor invaded the
pylorus. Lymph node dissection was performed according
to the second edition of the Japanese Classification of
Gastric Cancer [14]. Specifically, patients with T1 and N0
tumors underwent dissection of the perigastric lymph
nodes and nodes at the base of the left gastric artery, and
along the common hepatic artery, which for simplicity is
termed ‘D1+ lymph node dissection’ in this study. Patients
with T2 or more advanced tumors and those with N1 or
more advanced cancer underwent D2 lymph node dissec-
tion, which involves dissection of hepatoduodenal nodes
and retropancreatic nodes.
Hospital records were reviewed for age, sex, height,
body weight, clinicopathological background data re-
garding UICC-TNM stage, and surgical procedure. This
study was approved by the Human Ethics Review
Committee of the Osaka Medical Center for Cancer
and Cardiovascular Diseases.
Quantification of visceral fat area
The VFA was measured using ‘FatScan’, as described previ-
ously [15], on one cross-sectional CT image obtained at
the level of the umbilicus. Figure 1 shows the method used
to determine the fat tissue area on a CT image. First, the
intraperitoneal area was defined manually by tracing its
contour on the scan (Figure 1a). Thereafter, a region of
interest of the subcutaneous fat layer was defined by
tracing its contour on each scan, either automatically or
manually (Figure 1b), and then the attenuation range ofethod used to determine abdominal fat distribution. (a) The line
ith a cursor automatically or manually, outlines the subcutaneous fat
(in Hounsfield units) in the area outlined in b (mean ± 2 SD).
resented by the region outlined by the circumference of the
s regarded as the subcutaneous fat area (dotted arrow).
Table 1 Comparison of clinical background data of patients who underwent distal gastrectomy-Billroth I and distal
gastrectomy-Roux-en-Y
DGBI n = 104 DGRY n = 48 P
Age (years) 64 (38 to 85) 62.5 (37 to 80) 0.2574c
Sex (M/F) 69/35 37/11 0.1804a
BMI (kg/m2) before surgery 22.8 (16.0 to 30.5) 22.4 (17.1 to 31.0) 0.7243c
VFA before surgery (cm2) 75.2 (15.9 to 265.4) 80.6 (14.6 to 236.7) 0.9148c
SFA before surgery (cm2) 122.5 (35.5 to 267.3) 113.8 (14.9 to 231.5) 0.4142c
Albumin level before surgery (mg/dl) 4.3 (2.5 to 4.8) 4.1 (2.8 to 4.7) 0.0128c
Approach (laparoscopy/laparotomy) 15/89 0/48 0.0030b
Lymph node dissection (<D2/≥D2) 59/45 20/28 0.0840a
Omentectomy (yes/no) 13/91 15/33 0.0056a
Pathological T (1/2/3/4) 74/28/2/0 32/12/4/0 0.4420d
Pathological N (0/1/2/3) 78/20/6/0 34/10/3/1 0.5484d
Pathological stage (1/2/3/4) 86/11/7/0 37/5/5/1 0.3587d
Adjuvant chemotherapy (yes/no) 10/94 5/43 1.0000b
Recurrence (yes/no) 4/100 3/45 0.5110b
aχ2 test; bFisher’s exact test; cWilcoxon rank sum test; dMann-Whitney U test. BMI body mass index, DGBI distal gastrectomy with Billroth I, DGRY distal gastrectomy
with Roux-en-Y, SFA subcutaneous fat area, VFA visceral fat area.
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was calculated. A histogram for the fat tissue was com-
puted, based on the mean attenuation ± 2 SD (Figure 1c).
Within the region outlined in Figure 1a, the tissue with
attenuation within the mean ± 2 SD was considered to be
the VFA (white arrow, Figure 1d). The total fat area was
calculated in the region outlining the circumference of the
abdominal wall. The VFA was subtracted and the remain-
der was regarded as the subcutaneous fat area (black
arrow) (Figure 1d).
Statistical analysis
Differences between groups were examined for statistical
significance using the Student’s t test with Yates’ correc-
tion, the χ2 test, Fisher’s exact probability test, Wilcoxon
rank sum test, or the Mann-Whitney U test. Univariate
analysis was performed to identify the factors that deter-
mined visceral fat loss. The identified variables wereTable 2 Comparison of indexes of adiposity among patients w
gastrectomy-Roux-en-Y
DGBI n = 104
BMI after surgery 20.4 (15.0 to 28.1)
VFA after surgery (cm2) 50.8 (6.4 to 167.1)
SFA after surgery (cm2) 81.14 (19 to 230.8)
Alb after surgery (mg/dl) 4.3 (2.4 to 4.7)
Reduction rate of BMI (%) 8.7 (−15 to 31.2)
Reduction rate of VFA (%) 30.6 (−130.2 to 90.1)
Reduction rate of SFA (%) 33.0 (−124.6 to 82.3)
aWilcoxon rank sum test. BMI body mass index, DGBI distal gastrectomy with Billrot
VFA visceral fat area.subsequently entered into a multivariate analysis using
logistic regression analysis to identify independent fac-
tors that influenced the visceral fat loss. Significance was
assumed for P < 0.05. Statistical analysis was performed
using JMP version 9.0 (SAS Institute Inc, Cary, NC).
Results
Comparison of patients’ characteristics according to
surgical procedure
Table 1 compares the background characteristics of pa-
tients who underwent DGBI and DGRY. Age, sex, body
mass index (BMI), and VFA before surgery were not dif-
ferent among the groups. At baseline, the serum albumin
concentration was significantly higher in the DGBI (4.25 ±
0.36 mg/dl) than in the DGRY group (4.11 ± 0.36 mg/dl,
P = 0.0317).
With regard to the surgical factors, there was a significant
difference in surgical approach (that is, the proportion ofith distal gastrectomy-Billroth I and distal
DGRY n = 48 P
19.7 (16.9 to 26.2) 0.3789a
37.4 (11.7 to 144.5) 0.0742a
69.9 (23.5 to 184) 0.0808a
4.2 (3.7 to 4.6) 0.3065a
10.8 (−2.7 to 22.5) 0.1678a
44.2 (−14.5 to 85.2) 0.0027a
31.8 (−147.7 to 87.4) 0.5722a
h I, DGRY distal gastrectomy with Roux-en-Y, SFA subcutaneous fat area,
Table 3 Results of univariate analysis for visceral fat loss after gastrectomy
Univariate analysis High VFA loss group Low VFA loss group P
Sex (M/F) 53/23 53/23 1.0000a
Adjuvant chemotherapy (yes/no) 14/62 1/75 0.0006b
Reconstruction (BI/RY) 45/31 59/17 0.0146a
Lymph node dissection (<D2/≥D2) 30/46 49/27 0.0020a
Pathological stage (1 to 2 / 3 to 4) 64/12 75/1 0.0023b
Omentectomy (yes/no) 23/53 5/71 0.0003b
Surgical approach (laparoscopy/laparotomy) 4/72 11/65 0.1002b
aχ2 test; bFisher’s exact test; BI Billroth I, RY Roux-en-Y, VFA, visceral fat area.
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between the DGBI and DGRY groups (P = 0.0030), and
in omentectomy between the DGBI and DGRY groups
(P = 0.0056).
Analysis of the pathological factors and postoperative
clinical course showed that there was no significant
difference between the groups in pathological T, patho-
logical N, pathological stage, adjuvant chemotherapy, or
recurrence.
Comparison of BMI and VFA according to surgical
procedure
Table 2 lists comparative data related to BMI and VFA:
BMI after surgery and the rate of reduction of BMI
(ΔBMI%) were not different between the DGBI and
DGRY groups.
The VFA after DGBI (62.4 ± 39.8 cm2) was lower than
that after DGRY (50.7 ± 36.2 cm2), but the difference
was not statistically significant (P = 0.0742).
The rate of reduction of the VFA (ΔVFA%) in the DGBI
group (24.7 ± 36.8%) was significantly lower than in the
DGRY group (42.2 ± 24.1%, P = 0.0027). We also exam-
ined ΔVFA% in pathological stage I patients. The ΔVFA%
in the DGBI group (21.7 ± 38.1%) was significantly lower
than in the DGRY group (39.0 ± 24.4%, P = 0.0134).
Determinants of postoperative visceral fat loss
We examined the factors involved in visceral fat loss.
For this purpose, the study population was divided into
a ‘high VFA loss group’ and a ‘low VFA loss group’ using
the value of the median ΔVFA%, which was 36.1%. As
shown in Table 3, among the clinicopathological factorsTable 4 Results of multivariate analysis for visceral fat loss af
Multivariate analysis Hazard ratio
Adjuvant chemotherapy (yes/no) 5.0290
Reconstruction (BI/RY) 0.4249
Lymph node dissection (<D2/≥D2) 0.9539
Pathological stage (1 to 2/3 to 4) 0.4142
Omentectomy (yes/no) 0.4862
BI Billroth I, RY Roux-en-Y.examined, adjuvant chemotherapy (yes vs. no, P = 0.0006),
type of reconstruction (BI vs. RY, P = 0146), field of lymph
node dissection (<D2 vs. ≥D2, P = 0.0020), omentectomy
(yes vs. no, P = 0.0003), and pathological stage (1/2 vs.
3/4; P = 0.0023) correlated significantly with postoperative
visceral fat loss. Multivariate logistic regression analysis
that included these factors identified reconstruction
(BI vs. RY; P = 0.0232) and adjuvant chemotherapy (yes
vs. no, P = 0.0330) as the significant determinants of
visceral fat loss (Table 4).
Discussion
It is reported that body weight loss is mainly caused by
loss of body fat [12]. However, the effects of gastrectomy
procedures on postoperative visceral fat have not been
thoroughly examined. In this study, we analyzed the ef-
fect of surgical procedure on VFA. In the early postoper-
ative period, fat volumes are seriously affected by the
metabolic abnormality caused by surgery. Previous stud-
ies indicated that body weight loss occurs mainly during
the first 3 months after surgery [11]. Therefore, in this
study, we compared CT images taken at least 6 months
after surgery, when the nutritional status is presumed to
be stable [16].
A few studies examined changes in total fat or visceral
fat after gastrectomy. Liedman et al. [12] studied changes
in body composition by measuring total body potassium
and water in 75 patients with gastric cancer. They
observed a significant decrease in total body fat at 6
months after surgery but a subsequent marginal recovery
at 12 months. In another study, Kiyama et al. [13] evalu-
ated fat mass by multifrequency bioelectrical impedanceter gastrectomy
95% confidence interval P
1.1347 to 28.3460 0.0330
0.1965 to 0.8909 0.0232
0.4482 to 2.0343 0.9022
0.0723 to 2.0248 0.2774
0.1364 to 1.5993 0.2387
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decrease in body fat mass after TG than after subtotal
gastrectomy and laparoscopy-assisted gastrectomy. Yoon
et al. [17] reported a greater loss of visceral fat tissue after
TG than after subtotal gastrectomy at 6 months after sur-
gery. At 12 months after surgery, the losses in BMI, total
adipose tissue, subcutaneous, and visceral fat tissues were
all greater after TG than after subtotal gastrectomy.
Miyato et al. [16] reported that postoperative visceral fat
of the RY group tended to be smaller than that of the BI
group, although the difference was not statistically signifi-
cant, perhaps because of the small sample size. Based on
these differences, there is a possibility that the reconstruc-
tion procedure might have some effects on VFA.
The reasons for the differences in visceral fat reduc-
tion between BI and RY could not be elucidated in this
retrospective study. Previous studies on bariatric surgery
are of some help. It is reported that visceral fat reduction
was greater after RY gastric bypass than after vertical
banded gastroplasty [18]. Although the mechanisms of
fat reduction or improvement in insulin resistance are
not completely understood in bariatric surgery, the im-
portance of gut hormones has been reported. Among
the various gut hormones, gastric inhibitory polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1) are reported
to regulate fat metabolism. GIP is released from the duo-
denal endocrine K cells immediately after the absorption
of fat or glucose [19]. Furthermore, fat intake induces
hypersecretion of GIP, which increases nutrient uptake
and triglyceride accumulation in adipocytes [20]. In the
context of this study, Korner et al. [21] reported lower
GIP levels after RY gastric bypass than after adjustable
gastric banding, and concluded that the blunted GIP
secretion after RY seems to contribute to the greater
weight loss and improved glucose homeostasis compared
with adjustable gastric banding. GLP-1 is a naturally oc-
curring incretin hormone with a potent blood-glucose
lowering action only during hyperglycemia; a GLP-1
analogue reduces visceral fat [22]. Peterli et al. [23]
reported higher GLP-1 levels after RY gastric bypass
than after sleeve gastrectomy. The GIP level might also
be lower and the GLP-1 level might be higher after RY
than BI, and fat accumulation is lower after RY than BI.
Fat malabsorption might be another reason; since clin-
ical tests after RY showed significantly lower fat absorp-
tion than after BI and double-tract reconstruction,
which accommodated for the passage of food through
the duodenum [24].
As for omentectomy, our data showed that it was not
a significant determinant of visceral fat loss by multi-
variate analysis. There are some reports of surgical re-
moval of visceral fat thorough omentectomy [25,26].
There was no significant difference between RY gastric
bypass without omentectomy and with omentectomy infat mass 12 months after surgery [25]; this is compatible
with our result.
These results might be helpful in selecting the recon-
struction method used after distal gastrectomy, especially
for obese patients when remnant stomachs are large
enough so that either BI or RY could be performed. How-
ever, our study has several limitations. First, a retrospect-
ive sample was used in this analysis, and thus the clinical
background, such as extent of lymph node dissection,
omentectomy, and surgical approach, is different between
compared groups, although these factors did not correlate
with visceral fat loss in this study. Next, the size of
remnant stomach, which could affect the amount of food
intake after surgery, might be smaller after RY than after
BI, because the former construction technique was often
selected when the remnant stomach was too small to
allow for anastomosis with the duodenum. Third, the
long-term results are unknown, because we examined CT
data only 1 year after surgery.
Further prospective studies with stratified randomi-
zation and long-term follow-up data, such as VFA after 3
years or 5 years and cause of death, are needed to con-
firm the effects of reconstruction after gastrectomy on
visceral fat.
Conclusions
Visceral fat loss after RY was larger than that after BI. Fur-
ther prospective studies are needed to confirm the effects
of reconstruction after distal gastrectomy on visceral fat.
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